Wellgistics Health, Inc. (NASDAQ: WGRX) and DataVault AI, Inc. (NASDAQ: DVLT) entered into a software‑as‑a‑service agreement to develop PharmacyChain™, a manufacturer‑to‑patient blockchain‑enabled smart‑contract platform.
The partnership will embed PharmacyChain into Wellgistics’ existing digital prescription routing and AI‑powered hub fulfillment services, enabling pharmacies to securely transfer prescription data and automate reimbursement processes. Smart contracts will create a tamper‑proof record of each prescription from manufacturer to patient, facilitating faster insurance qualification and real‑time confirmation that patients receive their medication.
The companies will finalize a profit‑sharing license agreement in the fourth quarter of 2025 after identifying and valuing all potential revenue streams. Beta testing is slated for the first half of 2026, with a full commercial rollout planned for the second half of 2026. The platform targets the $639 billion prescription drug market and will leverage DataVault AI’s patented Information Data Exchange® technology and U.S. patents 12,100,025 and 11,960,622.
Wellgistics, which previously operated as Danam Health, Inc. until October 2024, currently connects 6,500 pharmacies and 200 manufacturers. DataVault AI, formerly WiSA Technologies, Inc. until February 2025, has a projected FY2025 revenue growth of 424 % but a negative EBITDA of $28.62 million. The collaboration aligns with Wellgistics’ strategy of combining logistics with advanced technology to improve patient access, price transparency, and medication adherence, while addressing regulatory requirements such as HIPAA compliance.
Leadership comments: Wellgistics President & Interim‑CEO Prashant Patel said the partnership “will create new revenue streams and improve patient outcomes,” and DataVault AI President & CEO Nathaniel Bradley highlighted the platform’s potential to “unlock data‑driven insights for manufacturers, pharmacists, and insurers.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.